DAB2IP and colon carcinoma: In colon carcinoma cells, reconstitution of DAB2IP limited the number of cancer stem cells (CSC)-like tumor-repopulating cells by impairing c-Myc expression [16], while in triple-negative breast cancer, DAB2IP-overexpression inhibited spheroid formation from single cells and reduced chemoresistance to docetaxel [36].